Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
CEO ReviewCompany Review

The Silicon Review Asia

Aurobindo Pharma Seeks to Add A Couple of Branded Products Acrotech Biopharma’s Portfolio

Aurobindo Pharma Seeks to Add A Couple of Branded Products Acrotech Biopharma’s Portfolio

Hyderabad based pharmaceutical manufacturing company, Aurobindo Pharma Limited, has been a bit slow on the acquisition front. It had made some key acquisitions in the past and is now considering to add a few branded products to its subsidiary, Acrotech Biopharma’s portfolio. After acquiring a portfolio of seven oncology injectable products from US-based Spectrum Pharmaceuticals Inc for $300 million, Acrotech Biopharma hopes to generate a revenue of around $100 million from it for the initial year after the completion of the transaction for Aurobindo.

At the Q3FY19 results conference call, N Govindarajan, Managing Director of Aurobindo Pharma, said that they keep evaluating their domestic business sometimes, but now they are prioritising to integrate what they have acquired. This could take time and therefore, they will just stick to adding a couple of branded products into the portfolio instead of making any large acquisition. He also said that Aurobindo Pharma will be overseeing the dietary supplements segment in India in the long-term as well as file approvals for at least two biosimilar products in 2020.“Subsequent year we should get approval as far as Europe is concerned as approval time is around 210-days if everything is in line in terms of the filing. As far as US is concerned, you should estimate around 12 to 18 months for approval from the date of filing”, he added.

Aurobindo Pharma hopes to commercialise its product in the Chinese market after two and a half years. Presently, it has received the permits for building its facility, set to be completed within a year.


Pine Labs Reaffirms its Commitment to Indian Payments Space with Qfix Acquisition

HDFC Bank is Qfix's main distribution partner Pine Labs has announced that it has acquired Qfix, a Mumbai-based online payments startup. This acquisi...

Salesforce Expands into Thailand, Opens Office in Bangkok

Salesforce has announced permanent presence in Thailand by launching its new office in the country’s capital, Bangkok. The permanent presence wi...

GMLL is expected to soon add two more stores to its retail arm ‘Price Mantra’

Garment Mantra Lifestyle, a popular name in the Indian fashion retail segment, recently made an announcement that the company is expanding its retail ...

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...